Nelonemdaz potassium Salfaprodil; Neu2000 potassium|cas:916214-57-8|西域试剂

Nelonemdaz potassium Salfaprodil; Neu2000 potassium,98.95%

产品编号：Bellancom-106408A| CAS NO：916214-57-8| 分子式：C₁₅H₇F₇KNO₃| 分子量：421.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-106408A	￥2500.00	杭州北京（现货）
Bellancom-106408A	￥4500.00	杭州北京（现货）
Bellancom-106408A	￥12500.00	杭州北京（现货）
Bellancom-106408A	￥18500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Nelonemdaz potassium Salfaprodil; Neu2000 potassium

产品介绍

Nelonemdaz (Salfaprodil) potassium 是一种 NR2B 选择性和非竞争性的 N- 甲基 -D- 天冬氨酸 (NMDA) 受体拮抗剂，也是一种自由基清除剂。Nelonemdaz potassium 对 NMDA 和自由基诱导的细胞死亡具有出色的神经保护作用。

生物活性

Nelonemdaz (Salfaprodil) potassium is an NR2B-selective and uncompetitive antagonist of N-methyl-D-aspartate (NMDA). Nelonemdaz potassium is also a free radical scavenger. Nelonemdaz potassium has excellent neuroprotection against NMDA- and free radical-induced cell death.

体外研究

Nelonemdaz potassium (10-300 μM) shows apparent neuroprotection against 300 μM N-methyl-d-aspartate (NMDA) at doses as low as 30 μM.
Nelonemdaz potassium (10-500 μM) inhibits the electrophysiologic response of cultured cortical neurons to 300 μM NMDA in a concentration-dependent manner.
Nelonemdaz potassium (0.1-1 μM) produces a marked reduction of Fe²⁺-induced neurotoxicity, even at doses of 0.1 to 0.3 μM.
Nelonemdaz potassium (0.1-1 μM) blocks the degeneration of neurons and glia in cortical cell cultures.
Nelonemdaz potassium (0-350 μM) effectively scavenges superoxide radicals (IC₅₀=63.07±1.44 μM), nitric oxide (IC₅₀=155.8±4.88 μM), and hydroxyl radicals (IC₅₀=58.45±1.74 μM).
Nelonemdaz potassium (0.78-12.5 μM) decreases the amount of antimycin A-induced ROS/RNS formation in a dose-dependent manner, with an IC₅₀ of 2.21±0.11 μM.
Nelonemdaz potassium (0.19-12.5 μM) inhibits malondialdehyde (MDA) formation with an IC₅₀ of 2.72±0.26 μM.
Nelonemdaz potassium (0-125 μM) effectively reduces iron-ascorbate-induced lipid peroxidation (IC₅₀=24.56±0.07 μM).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Nelonemdaz potassium (0.5-20 mg/kg; i.v.) reduces cerebral infarct evolving 24 h after 60-mins occlusion of the middle cerebral artery occlusion (MCAO) substantially and dose dependently.
Nelonemdaz potassium (5 mg/kg; i.v.) protects white matter such as axons and myelin as well as gray matter from ischemic brain injury.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (260 to 300 g) (clip occlusion model)
Dosage:	0.5-20 mg/kg
Administration:	I.v. administration 5 mins after reperfusion
Result:	Produced a large neuroprotective effect, with a maximal reduction in infarct volume of 66% at doses of 2.5 to 5 mg/kg. Not observed neuronal damage in the most vulnerable cortical area after administration of 5 mg/kg.

Animal Model:	Male Sprague-Dawley rats (260 to 300 g) (intraluminal thread occlusion model)
Dosage:	5 mg/kg
Administration:	I.v. administration 30 mins after reperfusion
Result:	Did not change physiologic variables such as arterial pH, PCO₂, PO₂, and hematocrit. Reduced infarct volume evolving in the cortex and the striatum substantially. Reduced white matter damage in the striatum and external capsule markedly.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (260 to 300 g) (clip occlusion model)
Dosage:	0.5-20 mg/kg
Administration:	I.v. administration 5 mins after reperfusion
Result:	Produced a large neuroprotective effect, with a maximal reduction in infarct volume of 66% at doses of 2.5 to 5 mg/kg. Not observed neuronal damage in the most vulnerable cortical area after administration of 5 mg/kg.

Animal Model:	Male Sprague-Dawley rats (260 to 300 g) (intraluminal thread occlusion model)
Dosage:	5 mg/kg
Administration:	I.v. administration 30 mins after reperfusion
Result:	Did not change physiologic variables such as arterial pH, PCO₂, PO₂, and hematocrit. Reduced infarct volume evolving in the cortex and the striatum substantially. Reduced white matter damage in the striatum and external capsule markedly.

性状

Solid

溶解性数据

In Vitro:

DMSO : 200 mg/mL (474.71 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3735 mL	11.8677 mL	23.7355 mL
5 mM	0.4747 mL	2.3735 mL	4.7471 mL
10 mM	0.2374 mL	1.1868 mL	2.3735 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

参考文献